Article
Simultaneous inhibition of PI3Kα and EZH1/2 suppresses <i>PIK3CA</i> helical domain mutated CRC by promoting IL15-mediated activation of NK cells
2026-06-17
Abstract excerpt
The PIK3CA gene encodes p110α, the catalytic subunit of phosphoinositide 3-kinase (PI3K), and is among the most frequently mutated oncogenes in multiple cancers, including breast and colorectal cancer (CRC) 1 . Two FDA-approved PI3Kα-specific inhibitors, Alpelisib and Inavolisib, are currently used in combination with fulvestrant to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-n...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- e06abd6b-157a-5699-9ed2-3ef34e18f54d
- DOI
- 10.64898/2026.06.16.732619
